GlaxoSmithKline - International Biopharmaceutical Industry

news

GSK loses R&D chief Barron to high-powered startup amid investor pressure

Hal Barron, GlaxoSmithKline's top scientist and architect of the company's plans to revitalize its drug research, will step down from his role later this year to lead...

20 January 2022 news Barron | Biotech

Continue Reading →

news

Adagio, after bold promises, says antibody drug won’t work well against omicron

The findings are a huge disappointment for Adagio, which billed ADG20 as a weapon that could neutralize a wide range of variants and help with future outbreaks. The c...

16 December 2021 news Adagio | ADG20

Continue Reading →

news

AstraZeneca wagers $200M on Ionis’ next chance at a rare disease drug

AstraZeneca is betting that Ionis' second drug for transthyretin amyloidosis, or ATTR, will stand out where its first one couldn't. Ionis developed Tegsedi for years...

10 December 2021 news AstraZeneca | ATTR

Continue Reading →

news

Pfizer, marking fast research pace, starts key trial of RSV vaccine

A vaccine against RSV has proven elusive despite decades of attempts. Pfizer is moving at a surprisingly quick pace to catch up to rivals led by GlaxoSmithKline, who ...

3 September 2021 news GlaxoSmithKline | GSK

Continue Reading →

news

Pfizer’s fast progress shines spotlight on an emerging vaccine race

Drugmakers have laboured for decades to successfully develop a vaccine to protect infants and older people against infections of a common pathogen called respiratory ...

5 August 2021 news drugmakers | GlaxoSmithKline

Continue Reading →

news

AstraZeneca wins first FDA approval for systemic lupus drug in a decade

Benlysta's approval was itself a landmark, being the first such drug approved in decades. Its use has grown slowly and steadily over time, falling just shy of blockbu...

5 August 2021 news AstraZeneca | Benlysta

Continue Reading →